ViroPharma's $4.2B Deal is Nothing to Sneeze At

By John George | Philadelphia Business Journal
|  Monday, Nov 11, 2013  |  Updated 5:37 PM EDT
View Comments (
)
|
Email
|
Print
$4.2B Pharma Deal Nothing to Sneeze At

advertisement

Long before its focus on rare diseases fueled a $4.2 billion merger deal with Shire Pharmaceuticals, ViroPharma had a much simpler target for its first product.

The Exton, Pa., biopharmaceutical company was out to develop a treatment for the common cold.
ViroPharma (NASDAQ: VPHM) was founded in 1994 and went public in 1996, raising $15.8 million in its IPO.

The company was built around developing Pleconaril, a drug candidate discovered by a team of scientists —including ViroPharma co-founder Claude H. Nash — working at Sterling Pharmaceuticals in Collegeville, Pa. ViroPharma licensed Pleconaril from Sanofi (NYSE: SNY), a French pharmaceutical company that acquired Sterling. Read more about this story on PBJ.com

More NBC10.com stories:

For more breaking business news go to PBJ.com

Get the latest headlines sent to your inbox!
View Comments (
)
|
Email
|
Print
Leave Comments
What's New
FlyeredUp: Win 2 Tickets to Flyers Playoff Game
Win two tickets to the first 2014... Read more
Follow Us
Sign up to receive news and updates that matter to you.
Send Us Your Story Tips
Check Out